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Abstract
Background: The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in
patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer.
Methods: The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic
metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer
were considered to avoid histology as a confounding factor. An illness-death model was employed to model the
relationship between LC and OS.
Results: Three hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included
and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with
112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was
27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT.
The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months
indicating better survival with LC.
Conclusion: In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by
achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.
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Background
Colorectal cancer (CRC) is the third most common ma-
lignancy with a global burden expected to increase to
2.2 million new cases and 1.1 million deaths by 2030 [1].
Liver is the most common site of CRC metastasis and
patients with liver metastases have been found to have a
particularly poor prognosis with significantly reduced
overall survival (OS) [2]. Still, in selected CRC patients
with limited liver or lung metastases longer-term sur-
vival can be achieved with complete surgical resection of
all metastatic lesions reaching 5-year OS rates up to 40%
[3, 4]. Due to technological innovations and based on
positive experiences with treating primary non-small cell
lung cancer (NSCLC) patients, stereotactic body radio-
therapy (SBRT) is increasingly adopted to treat pulmon-
ary and hepatic metastases. So far, however, dose
prescriptions have been mostly based on the experiences
made with primary NSCLC in case of pulmonary metas-
tases or on maximally tolerable doses for organs at risk
in case of liver irradiation. Prospective studies investigat-
ing optimal dosing schedules are lacking for SBRT of
extra-cranial metastases in general. For CRC metastases
in particular, some have even claimed that the site of
metastatic growth has an influence on radiosensitivity
and thus local control (LC) probability [5]. To our
knowledge, however, this has not yet been studied using
sophisticated models of patient outcomes since no suffi-
cient data has been collected so far.
An even more pressing question in this context is what
value optimizing the probability of LC would have for
longer-term OS. The rationale for using SBRT to treat
extra-cranial metastases was partly based on the observa-
tion that patients with a limited number of pulmonary,
hepatic or brain metastasis experienced survival benefits
after complete surgical resection [6]. Hints for similar ben-
efits of extra-cranial SBRT have so far been obtained in
single-institutional studies of a small number of subjects
[7]. Recently, a multicenter randomized phase II study for
oligometastasized NSCLC could demonstrate a signifi-
cantly improved progression-free survival with local treat-
ment in patients responding to first-line chemotherapy
versus maintenance chemotherapy alone [8]. The recently
presented outcome data of the EORTC-NCRI CCSG-ALM
Intergroup 40,004 trial could demonstrate for the first time
a positive effect of a local ablative therapy in the form of
radiofrequency ablation on OS in patients with liver me-
tastases from CRC in addition to chemotherapy [9].
Sophisticated modeling of the putative importance of
achieving LC for OS has not yet been performed, but
may - with the scarce prospective data available - aid in
the decision making on local treatment in oligometasta-
sized patients. To address this highly relevant issue we
have compiled the largest sample of colorectal lung and
liver metastases treated with SBRT from two separate
databases of the SBRT working group of the German So-
ciety for Radiation Oncology (DEGRO). This will be
used to model the outcome after SBRT with regard to
LC as well as OS with an emphasis on the role that the
site of metastasis might play.
Methods
Data preparation
The analysis is based on pooled data from two large
retrospective databases of SBRT treatments for pulmon-
ary and hepatic metastases compiled from a total of 27
German and Swiss hospitals, all members of the DEGRO
SBRT working group. All treatments performed on colo-
rectal cancer patients were pooled into a new database,
totaling 538 individual metastases treated with SBRT.
Detailed descriptions of the separate databases have
already been published [10, 11]. The multicenter data
collection and analysis was approved by the respective
local Ethics committees of the principle investigator’s in-
stitutions. For the current study, we excluded 38 metas-
tases with no post-treatment evaluation of LC or OS,
resulting in 500 metastases belonging to 388 patients.
All clinical and treatment related variables relevant for
the current analysis are compiled in Table 1.
Local recurrence for the SBRT treated lesions was de-
fined as either reappearance after complete remission or
re-growth after initial partial response to SBRT in follow-
up CT or MRI scans. PET-CT scans were used by some
centers in equivocal cases to confirm local recurrence. In
case that death and local failure were recorded at the same
date (this was the case for only 2 metastases), we adopted
the convention that death happened first and treated LC
as censored [12]. For modeling, all prescriptions were con-
verted to biologically effective doses at the isocenter de-
fined as BEDiso ¼ ndð1þ dα=βÞ where n is the number of
fractions, d the fraction dose at the isocenter and α/β as-
sumed as 10Gy.
The binary variable “chemotherapy prior to treatment”
was set to 1 if a patient had received chemotherapy prior
to SBRT at least once, and maximum tumor volume did
correspond to the largest metastasis treated. Table 1 pro-
vides details on all covariates and outcomes considered
for modeling.
Two hundred fifty-five patients were treated for a
total of 291 liver and 133 patients for a total of 209
lung metastases. In the dichotomization of the dose
calculation algorithm, “Advanced” refers to either Col-
lapsed Cone, Analytical Anisotropic Algorithm or
Monte Carlo based algorithms.
Model description
Our main interest lies in the relationship between LC
and OS. We model these two outcomes within the
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context of a multistate model, or more specific, a
so-called illness-death model [13] where death can occur
after local failure but not vice versa. In the illness-death
model there are three possible transitions (Fig. 1): (1)
treatment to relapse; (2) treatment to death; (3) relapse
to death.
We assumed proportional cause-specific hazards and
included frailty terms to account for possible heterogen-
eity between hospitals. For transition (1) the unit of
interest is the treated lesion. Clustering of metastases
within patients was neglected due to the very small
number of metastases associated with each patient. For
Table 1 Variables and outcomes in our sample of 500 CRC metastases
Covariates and outcomes n Value Liver Lung p-value
Sex 388
Male 271 69.8 72.2 65.4 0.200
Female 117 30.2 27.8 34.6
Age [years] 388 66 (24–93) 66 (24–93) 70 (38–36) 0.00399
Baseline Karnofsky index 283
< 90 97 34.2 30.6 40.9 0.125
≥90 186 65.7 69.4 59.1
Solitary metastasis 304
Yes 110 36.2 33.2 40.7 0.184
No 194 63.8 66.8 59.3
Number of treated metastases 388
1 321 82.7 89.4 69.9
2 42 10.8 8.2 15.8
3 13 3.4 1.6 6.8
4 7 1.8 0.4 4.5
5 2 0.5 0.4 0.7
6 3 0.8 0 2.3
Tumor site 500
Liver 291 58.2
Lung 209 41.8
Tumor volume [ccm] (gross tumor volume, GTV) 342 9.20 (0.07–699) 26.0 (0.8–699) 3.1 (0.07–268) < 0.0001
Chemotherapy prior to SBRT 430
Yes 332 77.2 84.5 68.5 < 0.0001
No 98 22.8 15.5 31.5
Dose calculation algorithm 496
Pencil beam 199 40.1 56.4 17.7 < 0.0001
Advanced 297 59.9 43.6 82.3
Motion management 500
Free breathing 347 69.4 75.3 73.7 0.755
Advanced 153 30.6 24.7 26.3
BEDiso [Gy10] 500 126.9 (37.5–309.4) 124.8 (37.5–234.5) 141.1 (39.4–309.4) < 0.0001
Outcomes 388
Local failure and censored prior to death 28 7.2 7.5 6.8 < 0.0001
Local failure and death 71 18.3 24.3 6.8
Death without local failure 133 34.3 36.5 30.0
Censored prior to local failure or death 156 40.2 31.8 56.4
Values for continuous variables are given as median (range), those for categorical variables as frequencies in percent. The p-values refer to testing for differences
between liver and lung metastases with respect to the variable specified in each row. The Wilcoxon rank sum test and Fisher’s exact test were used to compare
continuous and categorical variables, respectively. The variable “solitary metastasis” was coded as “yes” if only lung or liver was involved by a singular metastasis.
Beyond this information, the exact location and number of additional metastases has not been encoded
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transitions (2) and (3) the unit of interest was the pa-
tient. For all three transitions the clustering of patients
within hospitals was accounted for using a shared frailty
model [14]. In case of multiple treatments we define the
first treatment as the time origin and time of the first re-
lapse as the failure time.
Let Tijk1 denote the time from treatment until relapse
for metastasis k belonging to patient j from hospital i
with k = 1,… , nij, j = 1,… , si and i = 1,… , h. Further-
more, let Tij2 denote the time from first treatment until
death for patient j. The three possible transitions are
then specified by the three cause-specific hazard
functions:
h1 tijk1jwi1;X ijk1
  ¼ h01 tijk1
 
exp XTijk1β1 þ wi1
 
; tijk1 > 0
ð1Þ
h2 tij2jwi2;X ij2
  ¼ h02 tij2
 
exp XTij2β2 þ wi2
 
; tij2 > 0
ð2Þ
h3 tij2j tijk1
 
;wi3;X ij3
  ¼ h03 tij2j tijk1
  
exp XTij3β3 þ wi3
 
;
tij2 > tijk1
ð3Þ
Here wi = (wi1,wi2,wi3) is a vector of hospital-specific
random effects (each belonging to one of the three tran-
sitions) and βg, g ∈ {1, 2, 3} denotes the transition-specific
fixed effects. The random effects wi were assumed to
stem from a Gaussian distribution with mean 0 and vari-
ance σ2i .
The hazard h3 in Eq. (3) defines the rate of death of
patient j from hospital i following the occurrence of
local failure at time Tijk1 = tijk1. This hazard principally
depends on the set of failure times ftijk1gk¼1;…;nij of the
nij metastases of patient j. To simplify we apply the Mar-
kov assumption, h3(tij2| {tijk1}) = h3(tij2), in which the haz-
ard of death does not depend on the particular time of
tumor recurrence. This can be interpreted as stating that
a patient’s risk of death at any time after the first SBRT
is initially described by the hazard in Eq. (2), but if and
when a local relapse has occurred takes on the form of
Eq. (3) [13]. The hazard h3, which is estimated using pa-
tients that have experienced local relapse, is theoretically
defined for every patient beginning from the earliest
time point that a local relapse has been recorded in our
data (which was 2 months). The Markov assumption is
useful for inferring the general importance of achieving
LC for a patient’s probability of OS. In this case, the haz-
ards h2(tij2) and h3(tij2) correspond to the hazards of
death at time tij2 given that death has not occurred be-
fore tij2 and all metastases have been controlled or not
before tij2, respectively. The so-called explanatory hazard
ratio h3/h2 characterizes the dependence between Tij-
k1and Tij2. If h3/h2 = 1, the occurrence of Tijk1 has no ef-
fect on the hazard of dying at Tij2, while when h3/h2 > 1
at tij2 this indicates that for a fixed value of the frailty
and covariates, the risk of death is higher if a relapse
had occurred before tij2 [15].
Alternatively, one could think of treating local failure
as a time-dependent covariate Zj(t) which takes on value
0 as long as LC is achieved, but jumps to 1 if local fail-
ure occurs in patient j. In this case, the hazard of death
would be hðtijjwi;X ijÞ ¼ h0ðtijÞ expðZ jðtÞβ0þXTij βþ wiÞ
so that h2 and h3 would have the same baseline hazard,
their ratio would be given as h3/h2 = exp(β0), and h1
would be left unspecified. These restrictions do not
apply to the illness-death model whose structure natur-
ally accounts for the relation between LC and OS.
Models were fit using maximum integrated partial
likelihood estimation by the Laplace approximation with
the R package coxme. The refine.n option was used to
confirm the goodness of the Laplace approximation via
Monte Carlo control sampling.
Given a specification of the baseline hazard function,
the probability of local failure or death between time t
and horizon time t +w can be estimated. We therefore
complemented the analysis by approximating the base-
line hazard function on the basis of cubic M-splines that
were fit using the frailtypack package [16]. A lognormal
frailty was used which is equivalent to Gaussian random
effects [14]. The frailtypack routine uses maximum
Fig. 1 Conception of the illness-death modeling framework applied
to the study of local failure and death in metastatic rectal cancer
patients treated with SBRT. Starting from the state “SBRT treatment”,
patients can either transition into the state “Local failure” (the non-
terminal event occuring at time T1) or “Death” (the terminal event
occurring at time T2). A third transition from “Local failure” to
“Death” is also possible, but not vice versa. The rates at which
patients transition from one state to the other are specified by three
corresponding hazard functions that we model using Eqs. (1–3).
h1(t1) is the hazard rate for local failure from SBRT at a given point in
time t1, given that neither local failure or death have occurred
before t1. h2(t2) is the hazard rate for death after SBRT at a given
point in time t2, given that neither local failure nor death have
occurred before t2. Finally, h3(t2 ∣ t1) is the hazard rate of death at a
given time point t2 given that local failure has been observed at T1
= t1 and that death has not occurred before t2
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penalized likelihood estimation based on the robust
Marquardt algorithm [16]. For each transition, the num-
ber of knots for the splines was set to 9 and the optimal
smoothing parameter κ in the penalized log likelihood
was estimated by cross-validation [16].
Variable selection and model preparation
For survival regression, it is generally recommended to
restrict the number of covariates to approximately the
number of events divided by 15 [17]. We tried to use
this as a constraint to select an appropriate number of
covariates for each of the three transitions (Eqs. 1–3)
from the full set shown in Table 1 based on clinical
interest and knowledge from previous modeling studies.
Chemotherapy prior to SBRT treatment (missing for
14% of metastases) and tumor volume (missing for
31.6%) were judged as putative prognostic factors for
LC, and baseline Karnofsky performance score (KPS,
missing for 27% of patients) as well as presence of mul-
tiple metastases (missing for 21.6%) as possible prognos-
tic factors for OS. We imputation by chained equations
(mice) [18] to impute the missing values for these covar-
iates in order to maximize the number of cases for mod-
eling. The ideal set of predictors for each variable was
determined with help of the mice package function
quickpred by requiring a minimal correlation of 0.2
and minimum proportion of usable cases of 0.25. For
99 of the 158 lesions with unknown tumor volume,
the PTV volume was available and used in the imput-
ation. Sensitivity to the particular imputation of the
variables was checked by performing a total of 50 im-
putations, each time refitting the models and pooling
the results together using the pool function from the
mice package in R [18].
All covariates except BEDiso and tumor volume were
categorized to 0/1; BEDiso and tumor volume were stan-
dardized by subtracting the mean and dividing by two
standard deviations [19].
Statistical tests
Fisher’s exact test and the Wilcoxon rank sum test were
used to compare categorical and continuous variables,
respectively, between liver and lung metastases.
Two-sided Wald tests were used to obtain p-values for
regression coefficients.
Results
In total, 388 patients with 500 metastatic lesions (lung n
= 209, liver n = 291) were included and analyzed. Most
frequent dose prescriptions were 5 × 7 Gy @65% isodose
line (11.6% of metastases), 1 × 24Gy @80% (7.4%) and
3 × 12.5 Gy @65% (5.4%). Chemotherapy was signifi-
cantly more often administered prior to SBRT of liver
(84.5%) compared to lung (68.5%) metastases (Table 1).
Also, lung metastases received significantly higher
BEDiso than liver metastases. Tumor volumes were sig-
nificantly larger in liver compared to lung metastases,
and advanced dose calculation algorithms were used sig-
nificantly more often for planning treatment of the lat-
ter. Due to these differences the site of tumor location
was included as an important confounding factor into
each of the following models.
Median follow-up time for LC was 12.1 months (range
0.03–95.7) and 17.8 months (0.16–151.8) for OS. There
were 3 metastases in 2 patients that were lost to LC as-
sessment directly after the end of SBRT treatment which
explains the short FU duration of 0.03 months; both pa-
tients died 21 and 53 days after beginning of SBRT,
respectively. In total, 99 patients with 112 lesions experi-
enced local failure. Seventy-one of these patients have
died after experiencing local failure. Median survival
time was 27.9 months (95% CI 24.4–31.8) in all patients
and 25.4 months (95% CI 23.6–33.0) versus 30.6 months
(95% CI 24.5–37.4) in patients with and without local
failure after SBRT (p = 0.19), respectively. Local relapses
were recorded in 31.3% of liver metastases compared to
10.0% of lung metastases (p < 0.0001).
Table 2 provides an overview of all covariates selected
for modeling each transition together with their regres-
sion coefficients. In the multivariable analyses, smaller
tumor volumes, advanced motion management and dose
calculation techniques were non-significantly associated
with higher LC rates; significantly better tumor control
was found for lung metastasis compared to liver metas-
tases, no prior chemotherapy and higher BEDiso.
Figure 2 shows the Kaplan-Meier tumor control prob-
ability (TCP) curves for both liver and lung metastases
together with the predictions of the lognormal frailty
model for an average treatment. In this context, “aver-
age” refers to the mean and most frequent value for con-
tinuous and categorical variables, respectively, of lung
and liver metastases. The model predicts that for a 90%
TCP at 2 years, BEDiso of 99 Gy10 (lung) and 187 Gy10
(liver) would be sufficient with no prior chemotherapy,
but 211 Gy10 (lung) and 300 Gy10 (liver) would be
needed if prior chemotherapy would have been given
(Table 3).
For patients without local recurrence, baseline KPS
and maximum tumor diameter were found to be signifi-
cant for OS. If and when local failure occurred, max-
imum tumor diameter remained highly associated with
worse OS, while there was a weaker, yet significant asso-
ciation for chemotherapy prior to SBRT to improve OS
(Table 2). We found that because of the significantly lar-
ger sizes of liver metastases, controlling for maximum
tumor diameter was important for diminishing an other-
wise significant effect of liver metastases predicting
worse OS in transition 2.
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Figure 3 shows the baseline hazard ratio (h03/h02) be-
tween death after local recurrence (transition 3) and
death without local recurrence (transition 2) as a func-
tion of time starting at 2 months, the earliest time of re-
currence recorded in our database. The baseline hazards
correspond to the hazard of death when all fixed and
random effects are zero. It can be clearly seen that from
about 10 months on, the baseline risk of death after local
failure significantly exceeds the baseline risk of death
without local failure, and the ratio increases with time
indicating better survival after LC is achieved. This im-
plies that if the overall prognosis is judged to be beyond
1 year LC is a decisive factor for OS.
Figure 4 shows the predicted cumulative probability of
dying without (transition 2) or after (transition 3) experi-
encing local recurrence. Two predictions for an average
patient with either lung metastasis (right panel) or liver
metastasis (left panel) are shown. The cumulative death
Table 2 Covariates selected for modeling each transition (Eqs. 1–3) and their estimated regression coefficients expressed as hazard
ratios
Transition Treatment to local failure (1) Treatment to death (2) Local failure to Death (3)
Covariates exp(β) 95% CI p-value exp(β) 95% CI p-value exp(β) 95% CI p-value
Sex: Female 0.97 0.65–1.44 0.867
Age≥ 66 1.13 0.75–1.69 0.564
KPS ≥ 90 0.47 0.29–0.78 0.0037 1.30 0.56–3.02 0.534
Tumor site: Lung 0.42 0.25–0.70 0.0010 0.89 0.56–1.41 0.611 1.30 0.56–3.05 0.537
Solitary metastasis: Yes 0.83 0.53–1.29 0.405 0.55 0.23–1.30 0.174
Number of treated metastases > 1 0.96 0.59–1.56 0.861
Chemotherapy prior to SBRT: Yes 3.64 1.58–8.36 0.0024 1.19 0.71–1.98 0.508 0.19 0.04–0.84 0.028
Tumor volume 1.20 0.89–1.63 0.232 1.99 1.47–2.69 < 0.0001 2.12 1.25–3.58 0.0053
Motion management: Advanced 0.81 0.49–1.34 0.411
Dose calculation: Advanced 0.86 0.55–1.34 0.497
BEDiso 0.39 0.25–0.64 0.00013
If a variable was not used as a covariate for modeling the hazard of a particular transition, its corresponding cell has been left empty. For Transition (2), tumor
volume refers to the maximum tumor volume of all treated metastases within a particular patient
KPS Baseline Karnofsky performance status
Fig. 2 Tumor control probability predictions for treatment of a lung and liver metastasis with an average dose of BED = 132 Gy10. The left panel
shows the prediction for a liver metastasis, the right panel for a lung metastasis. The black dotted line is a 95% CI for the black solid line based
on 500 Monte Carlo samples. In both cases the other treatment characteristics (motion management, dose calculation algorithm, chemotherapy
prior to SBRT) are the same. The Kaplan-Meier tumor control probability curves for liver and lung metastases are shown in red for comparison
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probability for dying after local recurrence is almost
equal for lung and liver metastases, with slightly differ-
ing 95% confidence bands indicating a similar effect of
local recurrence on OS. In contrast, the cumulative
probability of dying without experiencing local recur-
rence is higher in patients with liver than in patients
with lung metastases indicating a generally worse prog-
nosis of patients with liver compared to lung metastases.
Still, in both cases the probability of making the transi-
tion 3 (death after local recurrence) quickly exceeds that
for transition 2 (death without local recurrence), consist-
ent with the behavior of the baseline hazard ratio shown
in Fig. 3, underlining the impact of LC on OS.
Discussion
Although Hellman and Weichselbaum coined the con-
cept of oligometastases as a distinct state with its own
biology in 1995 [20], it only recently started to be more
thoroughly investigated in the context of SBRT [7, 21].
Nevertheless, up until recently, there was no clinical
proof that oligometastatic patients really do benefit from
local interventions such as surgery or SBRT. A possible
hint for a benefit could be derived from surgical series
indicating worse OS after microscopic incomplete resec-
tion compared to complete resection, indicating the
need for LC of the respective metastases [22]. With the
outcome of the EORTC-NCRI CCSG-ALM Intergroup
40,004 trial, the first prospective data showing a positive
effect of a local ablative treatment on OS – in this case
radiofrequency ablation - in patients with liver metasta-
ses from CRC became available [9].
On the other hand, SBRT series on oligometastatic
patients included most frequently a mixture of histolo-
gies rendering comparison with surgical series difficult
(e.g.,[6, 21–26]). The intend of this analysis therefore
was to focus on metastatic CRC patients only, to avoid
bias by histology and to investigate the effect of LC on
OS after SBRT for lung or liver metastases. In addition,
we wanted to investigate the effect of metastatic site
(liver, lung) on tumor control rates, as there have been
Table 3 BEDiso converted to clinically applicable dose fractionation schedules to achieve at least 90% local control at 2 years of CRC
metastases
Tumor location No prior Chemo Prior Chemo
Lung 99 ± 15 Gy10 BEDiso 3 × 9 Gy @ 65% 211 ± 19 Gy10 BEDiso 3 × 15 Gy @ 65%
8 × 5 Gy @ 65% 5 × 10.5 Gy @ 65%
Liver 187 ± 19 Gy10 BEDiso 3 × 14 Gy @ 65% 300 ± 39 Gy10 BEDiso 3 × 18 Gy @ 65%
5 × 10 Gy @ 65% 5 × 13 Gy @ 65%
Fig. 3 Baseline hazard ratio between transitions 3 and 2 as a function of follow-up time after treatment. Ratios greater than 1 indicate a greater
risk of death if a patient has experienced a local recurrence prior to the time considered. The dashed lines indicate the 95% confidence band
based on 500 Monte Carlo simulations of the baseline hazards. A very similar trend is observed when computing the baseline hazard ratio for a
lung metastasis patient (coded with tumor site = 1), although the confidence bands are wider (not shown)
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observations that site-specific differences in the re-
sponse of CRC metastases to ionizing radiation might
exist [27–33].
Our analysis is the first to specifically address the
question whether the site of colorectal cancer metastases
plays a role in the response to SBRT treatment, but also
and even more importantly whether LC also translates
into improved OS. Applying an illness-death type multi-
state model to a total of 500 SBRT treatments of CRC
metastases, we studied differences between lung and
liver metastases with respect to LC and OS and the
interplay between both outcomes. The structure of the
illness-death model naturally accounts for the relation
between LC and OS which is not the case if LC would
be treated as a time-dependent covariate.
Dose-response analysis and factors influencing local
control
For achieving LC, we identified radiation dose or, more
precisely, BEDiso as the most important variable. How-
ever, the dose-response relationship was strongly influ-
enced by tumor site and whether chemotherapy had
been given prior to SBRT. The results are also in line
with our previous modeling studies of the full liver and
lung metastases cohorts from which the data analyzed
here had been extracted: Without taking any confound-
ing factors into account, the BED needed to achieve 90%
TCP after 1 year was estimated as 192 Gy10 (SE 37 Gy10)
for liver metastases [11], but 110 Gy10 (SE 17 Gy10) for
lung metastases [34]. Further data providing evidence
for an influence of tumor site on LC have been pub-
lished by Ahmed et al. [5] who reported 100% LC rates
at 2-years after SBRT treatment of CRC lung metastases,
but only 73.0% in liver metastases of similar sizes using
the same prescription of 60 Gy in 5 fractions. Although
their number of 29 lesions in total was small, these
differences were statistically significant (p = 0.026) and
attributed to differences in the parenchyma and vascula-
ture of liver and lung tissue [5]. A significantly larger α/
β ratio for hepatic compared to lung metastases, as re-
cently estimated in a meta-regression study by Klement
[35], would be consistent with such an explanation. In
contrast to the assumption of different site dependent
radiation sensitivity by Ahmed et al., another interpret-
ation for the difference in LC between lung and liver
metastases could be the challenges in target volume de-
lineation, image guided radiation delivery and motion
management technique. While this is supported by a
recent dose-response analysis of our large SBRT data-
base of lung and liver metastases, indicating that the
motion management technique significantly impacts LC
for liver, but not lung metastases ([11] and unpublished
data), the significance of tumor site persisted even after
controlling for motion management in our analysis. One
limitation of this analysis is that information on the
within-organ location of individual metastases was
Fig. 4 Cumulative probability of making transitions 2 (black) and 3 (red) as a function of follow-up time after treatment. Predictions are for an
average patient (male, KPS≥ 90, age < 66 years, one metastasis, given chemotherapy) with a liver (left panel) or lung (right panel) metastasis,
respectively. 95% confidence bands based on 500 Monte Carlo samples are shown as dotted lines. All predictions are averaged over different
imputations of the chemotherapy covariate. Note that after some short initial time the probability of transition 3 starts to exceed that of
transition 2, indicating a higher probability of death if the metastasis has not been controlled
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lacking; in the full lung metastases data set peripheral
tumor location (compared to central location) was asso-
ciated with improved TCP [34].
Our finding of chemotherapy prior to SBRT being a
negative predictive factor for LC is certainly intriguing
and needs further investigation. However, we believe that
this finding may explain the frequent notion that CRC
metastases (which are frequently heavily pre-treated) are
more radioresistant compared to other histologies [11].
Unfortunately, detailed information on the type of
chemotherapy was lacking, but in particular adjuvant
oxaliplatin (FOLFOX) therapy has been shown to be as-
sociated with worse outcomes in patients who later de-
veloped liver metastases, consistent with the increased
accumulation of new somatic mutations and acquire-
ment of therapy resistance [36]. Another explanation
might be that patients having received chemotherapy
prior to SBRT would be more likely to have node-posi-
tive primaries, indicative of more aggressive tumors.
The impact of local control on overall survival
The dependence of OS on LC is the most relevant find-
ing of this study. For the first time reported in SBRT
treated metastatic patients, a survival benefit was ob-
served, if LC of individual metastases has been achieved.
Our results are consistent with surgery outcomes show-
ing significantly longer 5-year OS after R0 compared to
R1 resection of hepatic metastases in CRC patients with
or without prior chemotherapy [22].
As Figs. 3 and 4 show, the probability of dying after a
local relapse soon exceeds that of dying if no relapse has
occurred. However, this difference becomes apparent
only after about 10 months of follow-up (separation of
the transition curves in Fig. 4), implying that LC impacts
OS if the projected prognosis is beyond this time point.
Conversely, if the projected survival is less than 10
months, achieving LC is clinically not relevant.
This finding directly relates to two important aspects
to achieve a possible survival benefit: patient and radi-
ation dose selection.
Selection of an appropriate radiation dose is directly
related to a previous analysis by our group developing a
model of TCP depending on both dose and time [34]. In
this model, the dose needed for a certain probability of
LC was time dependent: the longer the time interval the
higher the respective BED necessary for the same TCP.
Translated to our current findings this implies that if the
projected prognosis is beyond 12months, BED needs to
be high enough in order to assure long-term LC and im-
proved OS. Therefore, beyond an organs-at-risk adapted
dose selection, a time-adjusted BED with clinically rele-
vant LC (e.g. 90% TCP at 2 years) should be employed in
metastasized CRC patients with presumed longer-term
survival. Examples of such dose prescriptions based on
our model are given in Table 3. The high doses predicted
by our model as necessary to achieve high long-term
TCP in chemotherapy pre-treated metastases may be
very difficult to achievable clinically due to normal tissue
dose constraints, especially in the liver. However, besides
Fig. 5 Same as Fig. 4, but based on an analysis using only the subset of 311 metastases with no missing variables. Note that specifically for lung
metastases patients, the confidence bands are somewhat narrower than for the imputed dataset which could be explained by the larger variation
induced through pooling 50 different imputated datasates together as was done in Fig. 4
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the fact that these doses are not necessarily generalizable
to other target populations, they primarily highlight the
complicated interplay between patient prognosis and
dose escalation.
That the results of this retrospective study are specific
to our cohort and not necessarily generalizable to a dif-
ferent target population poses a major limitation for the
interpretation of our results. While similar analyses in
different cohorts and future prospective trials need to be
conducted, specifically the causal claim that LC influ-
ences OS would be further supported by studying poten-
tial underlying mechanisms [37]. Another limitation is
that our cohort lacked detailed information on the
pre-SBRT treatment history of individual patients, in
particular concerning types of chemotherapy and local
therapies such as previous liver or lung resections. It fol-
lows that patients probably had varying prognoses of
both LC and OS at the time of SBRT depending on fac-
tors that we were not able to account for in our model.
A prospective study with a more balanced patient co-
hort, possibly as a randomized trial applying different
fractionation schedules, would be very helpful for con-
firming our finding that achieving long-term LC has a
positive impact on OS. Finally, a large number of metas-
tases had at least one missing variable (189 or 37.8% of
the sample) which we decided to impute and which in
principal could have influenced our results. However,
re-analyzing the sample of 311 metastases with complete
entries, we obtained qualitatively similar results to the
main analysis, in particular regarding the importance of
predictors of transitions 1–3, and the impact of LC on
OS (Fig. 5).
Current patient selection criteria for local ablative
treatment are based on surgical analyses of oligometa-
static CRC patients with liver and lung metastases and
relate clinical parameters with prognosis. In optimally
selected candidates OS rates of up to 40% at 5 years
can be achieved for those patients. Conversely, even
patients who only fulfill a subset of these criteria may
benefit from local intervention. Therefore, a finer
grained approach would be desirable to estimate an in-
dividual’s projected survival based on a combination of
clinical parameters to guide the optimal decision re-
garding local ablative treatment. To this end, we re-
cently developed a nomogram for oligometastatic lung
disease treated with SBRT based on clinical parameters:
KPS, type of the primary tumor, control of the primary
tumor, maximum diameter of the largest treated metas-
tasis and number of metastases (1 versus > 1) [38].
These parameters are readily available and the nomo-
gram allows deriving 4 prognostic groups which could
serve as guidance for patient selection regarding local
ablative treatment of oligometastatic disease. Still, val-
idation of this nomogram in other metastatic disease
sites is warranted to generalize its applicability in oligo-
metastatic disease.
Conclusion
Utilizing a large patient cohort from a multi-institutional
database and focusing on CRC patients with lung or
liver metastases, the variables radiation dose, tumor site
and pre-SBRT chemotherapy could be identified as
predictive factors for LC after SBRT. Most importantly,
application of an illness-death model revealed an associ-
ation between achieving LC with SBRT and OS: patients
without local recurrence had a significantly lower risk of
death when adjusting for other influencing factors such
as tumor site (lung vs. liver), maximum tumor volume
or performance status. However, this was only observed
in patients with a projected OS estimate of approxi-
mately 12 months or more, underlining the importance
of proper patient selection for dose-intensified SBRT.
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